Codexis, Inc. (CDXS) Stock

Codexis, Inc. is a pioneering company focused on the discovery, development, and commercialization of enzymes and other proteins. Founded in 2002 and based in Redwood City, California, Codexis offers a diverse array of biocatalyst products and services. These include intermediate chemicals used in various chemical processes, as well as Codex biocatalyst panels and kits that facilitate chemistry screening for customers.

At the core of Codexis' capabilities is its CodeEvolver protein engineering technology platform. This innovative platform enables the development of biocatalysts optimized for specific chemical transformations, thereby enhancing manufacturing efficiency and productivity. Beyond industrial applications, Codexis leverages its platform to discover novel biotherapeutic drug candidates targeting human diseases, and to produce enzymes for molecular biology and in vitro diagnostics.

The company serves pharmaceutical manufacturers in the United States and Europe through a dedicated sales and business development force. In addition to its product offerings, Codexis provides biocatalyst screening and protein engineering services, reinforcing its commitment to delivering tailored solutions that meet the evolving needs of its global clientele.

Codexis continues to innovate at the forefront of biocatalysis, driving advancements in sustainable chemistry and biopharmaceutical development. With a strong emphasis on technology-driven solutions, Codexis remains a pivotal player in the biotechnology sector, dedicated to transforming industries and improving human health through cutting-edge enzyme technologies.